We use a patient-centric approach to identify and develop transformative medicines for the treatment of severe rare diseases. Our lead product candidate, apraglutide, is a next generation, long-acting synthetic GLP-2 analog which we are developing as a differentiated therapeutic for a range of rare GI diseases, with an initial focus on short bowel syndrome.
July 12, 2021
VectivBio Nominates Paul R. Carter and Murray W. Stewart for Election to its Board of Directors
- Industry veterans bring decades of clinical, regulatory and commercial management expertise to VectivBio - - Nominees will stand for election at an Extraordinary General Meeting of shareholders on September 2, 2021 - BASEL, Switzerland, July 12, 2021 (GLOBE NEWSWIRE) -- VectivBio Holding AG
June 24, 2021
VectivBio Receives FDA Orphan Drug Designation for Apraglutide for Acute Graft-Versus-Host Disease
Phase 2 trial expected to begin in the first quarter of 2022 BASEL, Switzerland, June 24, 2021 (GLOBE NEWSWIRE) -- VectivBio Holding AG, (“Vectiv” or “VectivBio”) (Nasdaq: VECT), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative